Q-omics provides the consensus-scored MYBPHL profile across patient tissues and cancer cell-line models. MYBPHL expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MYBPHL is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, MYBPHL RNA expression shows 14,296 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, HNSC, and UVM as cancer lineages where MYBPHL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYBPHL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYBPHL survival associations across molecular data types. MYBPHL RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYBPHL RNA expression–survival associations across cancer types. High MYBPHL expression shows unfavorable associations in LGG and LAML, but favorable associations in LUAD, PAAD, ACC and SKCM. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MYBPHL RNA expression.
This table summarizes MYBPHL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MYBPHL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYBPHL shows lower tumor expression in LUSC and LUAD and higher tumor expression in HNSC, THCA, COAD and LIHC. The HNSC box plot shows higher MYBPHL RNA expression in tumor versus normal tissue (log2 FC = +0.619, t-test p < 0.001).
This table shows molecular features associated with MYBPHL in patient tissues and cancer cell lines. In patient samples, MYBPHL shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYBPHL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
